SLC5A2 and diabetes mellitus: Furthermore, we could not account for specific medications commonly used in this patient group, including sodium‐glucose cotransporter‐2 (SGLT2) inhibitors or glucagon‐like peptide‐1 (GLP‐1) receptor agonists, which may confer protection against all‐cause and cardiovascular mortality by improving cardiovascular outcomes and glycaemic profile in diabetes (i.e., improving albumin levels.21